血清miR-139-5p在卵巢癌患者中的表达及其临床意义

Expression and clinical significance of serum miR-139-5p in patients with ovarian cancer

目的 探讨微小RNA-139-5p（miR-139-5p）在卵巢癌患者血清中的表达及其在诊断和预后判断中的临床价值.方法 选取本院2009年3月至2011年12月收治的34例浆液性卵巢癌患者及同期34例女性健康体检者的血清样本.利用荧光定量PCR （RT-qPCR）方法分别检测34例卵巢癌患者术前术后和34例健康对照妇女血清中miR-139-5p的表达情况,采用t检验进行统计学分析,并分析miR-139-5p在诊断和预后中的临床价值.结果 miR-139-5p在卵巢癌患者术前血清中的表达（9.45±0.40）显著高于健康对照组（3.56±0.10）,差异有统计学意义（t=14.340,P＜0.001）.卵巢癌患者术后1个月血清miR-139-5p表达水平（5.53±0.49）与术前相比显著降低,差异有统计学意义（t=7.800,P＜0.001）.术前血清miR-139-5p表达与卵巢癌患者淋巴结转移（P =0.038）相关,而与年龄（P =0.728）、临床分期（P =0.118）、肿瘤大小（P =0.732）及分化程度（P=0.071）无关.Kaplan-Meier生存曲线显示,miR-139-5p低表达的患者其中位生存时间（44.9个月）长于miR-139-5p高表达患者（25.9个月）,差异有统计学意义（x2 =5.721,P=0.017）.结论 miR-139-5p在卵巢癌患者血清中表达水平显著增高,可作为卵巢癌患者诊断和预后的潜在生物标志物.

Objective To explore the expressions and clinical values of serum microRNA-139-5p （miR-139-5p） in diagnosis and prognosis of patients with ovarian cancer.Methods From March 2009 to December 2011,a total of 34 patients with serous ovarian cancer and 34 female health examiners were collected in our hospital.The expressions of serum miR-139-5p before and after operation were detected in 34 patients with ovarian cancer and 34 healthy women by real-time quantitative polymerase chain reaction （RT-qPCR）.The data was analyzed by t-test.The clinical values of serum miR-139-5p in diagnosis and prognosis of patients with ovarian cancer were analyzed.Results The expression of serum miR-139-5p in patients with ovarian cancer （9.45 ± 0.40） was significantly higher than that in healthy controls （3.56 ± 0.10）,with a significant difference （t =14.340,P 〈 0.001）.The expression of miR-139-5p at 1 month after operation of patients with ovarian cancer （5.53 ± 0.49） was lower than that before operation,with a significant difference （t =7.800,P 〈0.001）.The expression of serum miR-139-5p was correlated with lymph node metastasis （P =0.038）,but was not correlated with age （P =0.728）,clinical stage （P =0.118）,tumor size （P =0.732） and differentiation （P =0.071）.Kaplan-Meier survival curve revealed that the median survival time of ovarian cancer patients with low serum miR-139-5p expression （44.9 months） was longer than that of patients with high serum miR-139-5p expression （25.9 months）,with a significant difference （x2 =5.721,P =0.017）.Conclusion The expression of miR-139-5p is increased significantly in the serum of patients with ovarian cancer,which can be used as a potential biomarker for diagnosis and prognosis of patients with ovarian cancer.